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, the late Henry S. Kaplan demonstrated that
the lymphoid cells of a nonirradiated mouse thymus may undergo neoplastic
transformation through mere residence within an irradiated host environment
(1-3). These results were later confirmed in other laboratories (4, 5) . It was
thereby established unequivocally that radiation lymphomagenesis in mice pro-
ceeds through an indirect mechanism of induction . Soon thereafter, a leukemo-
genic retrovirus, designated radiation leukemia virus (RadLV),' was isolated
from tumor tissue of C57BL/Ka mice with radiation-induced lymphomas (£r),
and by inference, the role of mediator was attributed to this virus. It was
postulated that RadLV, activated in the host by ionizing radiation, is released
and transported to the thymus, where lymphoblasts, generated during the
postradiation recovery phase, constitute an optimal target cell population for
both replication of and eventual transformation by virus (0-8) . When it
apparent that RadLV is found in only 5-10% of radiation-induced lymphomas
(9), the hypothesis required modification, and the concept of RadLV-0 was
introduced . In this formulation, RadLV is initially activated in a replication-
defective form (RadLV-0), in which only the oncogenic potential of the virus is
expressed (10) . Other investigators invoked the idea of somatic mutation to
explain radiation lymphomagenesis, stipulating that radiation initiates neoplastic
transformation of target cells in the bone marrow through a direct mutagenic
effect (I 1-13). The radiation-damaged thymus then provides asuitable environ-
ment in which preleukemic bone marrow cells evolve to full neopaasia with no
ity for viral mediation . However, since Kaplan's thymus graft experiments
with such direct transformation of bone marrow cells, and
o be identified, new hypotheses may be considered . We
undertook the present study to investigate the possibility that radiation lympho-
magenesis is mediated by a transmissible agent altogether different from RadLV.
To assess further the relative contributions ofbone marrow and thymic cells,
as well as the role of RadLV in the disease process, we reexamined the fate of
thymic grafts in irradiated hosts, using C57BL/Ka mice (Thy-1 .2)and a Thy-1 .1
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congenic substrain for this purpose. We also examined the lymphomagenic
potential of adoptively transferred bone marrow cells from irradiated mice to
evaluate their role as target cells for transformation, versus that of transmittors
of a lymphomagenic agent to thymic target cells. Our results demonstrate that
bone marrow is the site of the initial transforming event, but that T cell
lymphomas originate in the thymus. In most instances, the signal transmitted by
bone marrow is not identifiable as RaALV. The nature of this signal is the subject
of ongoing investigation. In addition to thymic lymphomas, radiation induces a
significant number of apparently Thy-1 - lymphomas, most of which express
markers characteristic of the B cell lineage.
Mice of strain C57BL/Ka, expressing the Thy-1 .2 determinant, and of the Thy-1
congenic substrain C57BL/Ka/Thy-1 .1 (hereafter designated BL/1 .1) were bred in our
colony. One strain served as donor, the other as recipient in experiments involving thymic
grafts and transfers of bone marrow or thymic cells. C57BL/6-Ly-5.2 mice were obtained
through the courtesy of Dr. E. A. Boyse (Memorial Sloan-Kettering Cancer Center, New
York).
Lymphoma Induction
Materials and Methods
Craft Experiments.
￿
Recipient mice were thymectomized at age 4 wk and started I wk
later on a leukemogenic course of four weekly, whole-body exposures to x radiation of
1 .75 Gy each. One thymic lobe from neonatal donor mice was placed under the kidney
capsule of the recipient, either 1 wk before the start of irradiation or within 24 h after its
completion.
Cell Transfer Experiments.
￿
One group of mice was thymectomized and irradiated as
described; the other was not thymectomized. On days 1, 10, 30, and 60 after the last
exposure, bone marrow suspensions were prepared from the leg bones of each mouse.
Recipient mice aged 5-6 wk were exposed to a single dose of x radiation of 5 Gy (which
is not by itself lymphomagenic) and, on the same day, injected intravenously with 1-2 x
10' donor cells, one donor to one recipient. Thymocyte suspensions were prepared at the
10-d interval only. Irradiated recipients were injected intrathymically with 5-10 x 106
cells.
Antibodies and Cell Surface Staining
A panel of mAbs was used to identify cell surface determinants on thymocytes in
repopulated grafts and on tumor cells. Fluorescein-conjugated anti-Thy-1 .2 mAb was
purchased from Becton Dickinson Immunocytometry Systems (Mountain View, CA). The
hybridoma cell line 19VE12, secreting mouse anti-Thy-1 .1 mAb, was kindly provided by
Dr. R. Nowinski (Hutchinson Cancer Research Center, Seattle, WA). Rat mAb RA3-6B2,
specific for the B220 antigen expressed on mouse cells of the B lineage, including pre-B
cells (14) was a gift from Dr. R. Coffman (DNAX Research Institute, Palo Alto, CA), as
was rat mAb RA3-8C5, specific for mouse granulocytes. Additional rat mAbs used were
1IB5 (15), which binds mouse IgM, and MI/70 (16), specific for the mouse macrophage
antigen Mac-1 . The unlabeled mAbs were concentrated by ammonium sulfate precipita-
tion from hybridoma culture fluids. Second-stage antibodies were fluorescein-conjugated
goat anti-mouse Ig (Tago, Inc., Burlingame, CA) and anti-rat Ig (Cappel Laboratories,
Cochranville, PA). Controls were treated with second-stage antibody alone. Preparation
ofcell suspensions and staining were carried out as previously described (17). The stained
cells were mounted in Cunningham chambers and examined with a Zeiss fluorescence
microscope under epi-illumination.Detection ofMuLV in Lymphoma Cells
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Cell suspensions were prepared from lymphomatous tissue (thymus or thymic graft
when possible) and processed as described (18) to detect the presence ofretroviral antigens
in the cytoplasm of cells by immunofluorescence. Briefly, cell suspensions were placed on
the wells of toxoplasmosis slides (Bellco Glass, Vineland NJ), air-dried, fixed in acetone,
and stained with a polyvalent anti-RadLV rat regressor serum (19) and fluorescein-
conjugatedsecond-stage anti-rat Ig. The preparation was counterstained with Evans Blue
stainto render nonfluorescent cells visible. By this method, a single fluorescent cell among
1-2 x 104 negative cells can be readily identified. However, unambiguous identification
of cells exhibiting low levels of fluorescence (i.e., containing low concentrations of viral
antigens) is difficult. Therefore an in vitro infectious center assay was also used. Radiation-
killed (100 Gy) lymphoma cells were cocultivated with cells of the lymphoma line
BL/RL12-NP (20), which does not produce retrovirus but is highly susceptible to infection
by RadLV, and consequently becomes immunofluorescence-positive. Medium from these
cultures was used for assays of reverse transcriptase (RTase) activity (21); in all tests,
immunofluorescence and RTase results coincided. In some instances, an in vivo infectious
center assay was carried out as well, in which radiation-killed tumor cells were injected
intrathymically in mice to test lymphomagenic activity. Where lymphomas developed,
they were in turn analyzed for expression of cell surface determinants (both to distinguish
host vs. donor origin, and to define the cell type transformed) and of RadLV.
Lymphoma Cell Cultures
To establish lymphomas in vitro, small pieces of tumor, together with tumor cells in
suspension were seeded in Iscove's medium supplemented with 10% FCS, 5 x 10-5 M 2-
ME, and antibiotics. Partial medium changes were carried out once or twice weekly until
the cultures were well established. Thereafter, the cultures were divided 1 :10 at 3-4-d
intervals.
Results
Lymphomas in Mice Bearing Thymic Grafts.
￿
Thymectomized, irradiated mice
that had received a thymic graft from Thy-1 congenic, neonatal donors either
before the start of the radiation regimen or on its completion were divided into
two groups, one to be used for examination of the grafts at 6 wk after their
implantation, the other to await lymphoma development. The grafts removed at
6 wk appeared normal and were repopulated by lymphoid cells. The genetic
origin of these cells was ascertained by their Thy-1 phenotype. When 85% or
more of cells in the population were of a given phenotype, that phenotype was
assigned to the entire population . When the proportion was less, the population
was deemed to be of mixed origin. By this criterion, all grafts implanted before
irradiation and most of those implanted thereafter were reconstituted by cells
originating in the irradiated host (Table I). Many of the grafted mice became
leukemic. In these animals, the graft was invariably enlarged, and its normal
thymic architecture was obliterated by tumor cells. The adjacent kidney, spleen,
liver, and lymph nodes were usually involved as well. In lymphomatous tissue,
the tumor cells were all of a single Thy-1 phenotype, without admixture of the
opposite type. In the group grafted before irradiation, most lymphomas (76%)
were of host origin (Table I). In contrast, tumors in mice bearing postradiation
grafts were predominantly (77%) of donor phenotype. The frequency of lym-
phomas was substantially reduced in this group (28 vs. 60%). RadLV-expressing
lymphomas did not exceed 10% of the total in either group of leukemic mice
(data not shown).1886
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TABLE I
Lymphocyte Derivation in Repopulated Thymic Grafts and
in Graft Lymphomas
* Thymectomized, irradiated (1 .75Gy, four doses) hostsand graftdonors differ
at Thy-1. Repopulated grafts were examined 6 wk after implantation.
$ Number of grafts showingindicatedphenotypeper number tested.
Number of leukemic mice per total.
Lymphomas in Recipients of Bone Marrow and Thymus Cells.
￿
In the preceding
experiment, the appearance of lymphomas in unirradiated grafts residing in
irradiated hosts could be explained by Kaplan's assumption that a leukemogenic
agent is transmitted from the host to thymic target cells. Transmission could
proceed via bone marrow cells migrating to the thymus, which transplantation
or irradiation has depleted of lymphocytes (7). On the other hand, development
oftumors derived from the host in mice grafted before irradiation lends support
to Haran-Ghera's view that bone marrow cells from irradiated mice may them-
selves undergo neoplastic transformation. It was therefore necessary to examine
further the role of bone marrow in radiation leukemogenesis. C57BL/Ka mice,
either intact or thymectomized, were exposed to the leukemogenic regimen of
radiation and used as bone marrow donors. The cells were collected at intervals
after radiation, and injected into congenic BL/1.1 recipients as described. Thy-
mocytes, harvested 10 d after the last x-ray exposure, were similarly injected.
Starting at ^-3 mo after cell transfer, lymphomas developed in 9 of 19 mice that
had received donor thymocytes (47%), and in 79 of 118bone marrow recipients
(67%) (Table II). Characterization of the tumors with respect to cell surface
determinants and RadLV expression yielded clear results: the T cell (Thy-1')
lymphomaselicited bybonemarrowinjection were exclusively ofrecipientorigin.
In contrast, lymphomas developing in thymocyte-injected mice were mainly of
donor origin. Neither time interval to bone marrow transfer nor donor thymec-
tomy significantly influenced tumor incidence or origin. Lymphomas that were
Thy-1- by the assay used occurred with remarkably high frequency in bone
marrow recipients (25 vs. 41% Thy-1+ tumors), but were not observed in
thymocyte recipients. Infectious RadLV was detected in 9% of Thy-1'' lympho-
mas and in 30% of Thy-1- tumors.
Phenotype of
lymphocytes
Host treatment*
Graft--* X ray(%) X ray--* Graft(%)
Repopulated grafts*
Graft donor
Host
0/12(0)
12/12(100)
4/59(7)
49/59(83)
Mixed 0/12(0) 6/59(10)
Graft lymphomas
Graft donor 6/25(24) 17/22(77)
Host 19/25(76) 5/22(23)
Mixed 0/25(0) 0/22(0)
Tumor incidence4 25/42(60) 22/78(28)Bone marrow
Thymocytes
Nonviablecells*
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TABLE 11
Characterization ofLymphomasInduced by Transfer ofCellsfrom Irradiated Mice
Cell donors
￿
Lymphomas in cell recipients
Cells trans-
ferred
* All donors were irradiated with 1.75 Gy of four doses. Bone marrow donors were either intact or
had been thymectomized before irradiation. At the indicated intervals after the last exposure,
donorcellswere injected into Thy-1 congenic, irradiated (5 Gy) recipients.
$ Cells were lethally irradiated (100 Gy)before injection.
Transmissible Leukemogen in Lethally Irradiated Cells. The host origin of
lymphomas induced by transferred bone marrow suggests the presence of a
subcellular, transmissible leukemogen(s). Because a fragile agent might be de-
stroyed in the course of preparing cell-free extracts, intact, lethally irradiated
(100 Gy) thymus and marrow cells, collected 10 d after the last x-ray exposure
were injected intrathymically in congenic mice. Lymphomas ofrecipient pheno-
type were induced (Table 11), more effectively by thymocytes than by bone
marrow; all but one were free ofdetectable RadLV. IfRadLV were nonetheless
the etiologic agent in the virus-negative lymphomas, but present at levels too low
to be detected, an additional round of infection should permit sufficient ampli-
fication ofthe virus toattain detectable levels. To evaluate thispossibility, several
RadLV-, Thy-1+, and Thy-1- lymphomas, as well as a small number of RadLV+
tumors were lethally irradiated and injected into congenic mice. Approximately
half the lymphomas tested were productive and induced tumors (Table 111).
Most were Tcell lymphomas ofrecipient phenotype, others were Thy-1-. Only
14% ofThy-1+ and 22% ofThy-1- lymphomas expressed RadLV. Although the
numberofRadLV+ lymphomas tested in this manner isvery small, it isofinterest
that only one of three tumors induced was virus positive. Moreover, tumors
induced by any one lymphoma did not necessarily match each other or the
Treatment*
Thymectomy
Time to
cell trans-
fer
d
1
Incidence
7/12
Thy-1*
tumors
host/donor
origin
5/0
RadLV`
0
Thy-I-
tumors
2
RadLV*
0
- 1 7/13 5/0 0 2 0
Thymectomy 10 11/15 8/0 0 3 2
- 10 10/13 6/0 1 4 2
Thymectomy 30 14/20 7/0 1 6 2
- 30 13/19 5/0 1 8 2
Thymectomy 60 9/11 4/0 0 5 1
- 60 8/15 8/0 0 0 0
10 9/19 1/8 2 0 0
Bone marrow 10 4/22 4/0 0 0 0
Thymocytes 10 6/23 6/0 1 0 01888
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TABLE III
Lymphomagenic Agent in Marrow ofIrradiated Mice: Further Evidence ofTransmissibility
* Lymphomas induced by transferred bone marrow cells from irradiated mice. Phenotypes were
Thy-1 (T) or 13220 (B).
$ RadLV expression is shown as + or -.
§ Number of primary lymphomas which, on transfer of lethally irradiated cells, induced lymphomas
in the hosts, pernumber of lymphomas tested.
PhenotypesandRadLVexpression as in primary lymphomas, with theaddition oftumors containing
both Thy-I and 13220-expressing cells (T/B), and tumors expressing neither determinant (0).
Numbers shown specifyindividual lymphomaswith the indicated characteristics.
parent tumor with respect to phenotype and expression of RadLV.
The Thy-1 - Lymphomas.
￿
Inmice with Thy-1-lymphomas, thelymphoid organs
were generally enlarged, but the thymus was normal-sized or atrophic, and there
was frequently ablood-tinged, cellular pleural effusion. Thehostvs. donororigin
of these tumors could not be ascertained in the absence of the Thy-1 marker.
Subsequently C57BL/6-Ly-5.2 mice were used as recipients of bone marrow
from BL/1.1 (Ly-5.1) irradiated donors, to take advantage of the presence of
the Ly-5 marker on both T and B lymphocytes (22). Preliminary data (three of
four lymphomas tested) suggest that the Thy-1- tumors are probably of donor
origin. In membrane immunofluorescence assays using mAbs to cell surface
antigens, only antibody RA3-6112, specific for the 13220 antigen expressed on
cells of the B lineage, was found to bind. Because mAb 11B5 did not bind,
surface IgM is presumably not available on the cells, and we assume that they
are at the pre-B stage. The relative abundance of 13220+ cells varied with
individual tumors, ranging from ^-20 to nearly 100% of the population. Four
13220' lymphomas were established in culture, but their phenotype proved
unstable. Three lines lost 13220 expression soon after becoming established and
became Thy-1'; the fourth line did so after 2-3 mo in culture. To determine
whether the Thy-1' cells in this line were clonally derived from 13220+ cells,
their immunoglobulin w arrangement was analyzed. The Thy-1' cells retain one
germline allele that is rearranged in the 13220' cells (data not shown), ruling out
progression ofa 13220'' phenotype to a Thy-l+ phenotype. In all cases, when the
cells became Thy-1', the recipient allotype was expressed.
Discussion
Although the induction of thymic lymphomas in mice by ionizing radiation
hasbeen the subjectofextensive study, the site oforigin ofthe neoplasticprocess
and the role of viral mediation are still incompletely understood. In the present
Primary
Pheno-
type
RadLV
sion$~
expres-
lymphomas*
Productive
tumors/
number
tested;
Incidence T
-
Host
Phenotypes
lymphomas
and
-
B
RadLV expression
0 _
-
T/B _
-
T - 14/17 18/47 10 2 1 1 3 1
B - 5/12 9/19 7 1 1 0 0 0
B + 2/3 3/5 1 0 0 1 1 0LIEBERMAN ET AL.
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experiments, we have more fully evaluated these issues, using C57BL/Ka mice
congenic at the Thy-1 locus. The results of this study both confirm previous
observations and force a reinterpretation of those observations. As in the past,
thymic cells are demonstrated unequivocally to be the target of transformation
by an entity carried within, and transmitted by, irradiated bone marrow cells. It
is now equally clear, however, that in the majority of cases, the transmissible
entity if not RadLV.
Thymic Cells Are the Target of Neoplastic Transforma
Agent(s) Induced in and Transmitted by Bone Marrow.
￿
As first shown by Kaplan
et al. (3), lymphomas appearing in thymectomized mice grafted with a neonatal
thymus after completion of a leukemogenic course of x radiation are predomi-
nantly ofgraft donor origin. These genesis was previously explained by assuming
the transmission of RadLV from the irradiated host to target cells in the
unirradiated thymic grafts (7). Ourpresent results indicate thatthe source ofthe
leukemogenic agent (probably not RadLV) is the bone marrow, and that
transported to the thymus by homingbone marrow cellsafter being activated by
radiation. The target cells for neoplastic transformation are the progeny ofhost-
derived marrow cells in grafts implanted before irradiation. In grafts implanted
after irradiation, the incoming, irradiated marrow cells presumably do not
constitute an appropriate target cell population, and surviving cellsofgraftorigin
are the target. The transmission of a lymphomagenic agent from the irradiated
marrow to the unirradiated thymus is further demonstrated by the induction of
'
￿
lymphomas on transfer ofbone marrow cells from irradiated donors to
congenic mice. In contrast, the transfer of thymocytes induces lymphomas of
donor origin under similar circumstances, demonstrating that these cells can be
transformed by the agent. Thymectomy does not preventactivation of the agent
in the marrow of irradiated mice, and, once activated, the agent appears to
persist for at least 2 mo. Our results are at variance with those of Haran-Ghera
(11, 12) who observed lymphomas of donor origin on transfer of bone marrow
cellsfrom irradiated C57BL/6 mice to (BALB/cx C57BL/6)F, hybrids. Possible
reasons for the difference include reduced susceptibility of hybrid recipients to
C57BL-derived agents and the evaluation of tumor origin on the basis of
transplantability. The presence of Thy-I was not determined, and the results
would therefore include both Thy-1* and Thy-1- tumors, while our data only
reveal the origin of T cell lymphomas.
Radiation Also Induces Pre-B Cell Lymphomas.
￿
C57BL/Ka mice exposed to
fractionated, whole-body x radiation develop a high incidence (90-100%) of
thymic lymphomas (23), but virtually no other malignancy. It was therefore
surprising to note the relatively high frequency of pre-B cell lymphomas in mice
injected with marrow from irradiated donors. Incomplete evidence indicates that
these tumors are of donor origin. They are presumably derived from bone
marrow progenitor cells in which the agent was activated, or from susceptible
cells in the marrow to which it was transmitted. Since lethally irradiated T and
pre-B lymphoma cells induce lymphomas of either class in recipient mice, it
appears that the same agent(s) is involved in both Tand pre-B lymphomagenesis.
RadLV in contrast is known to induce Tcell lymphomas only. The loss ofB220
expression and the appearance of Thy-1 on cultured lymphoma cells demon-1890
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strates that both classes oftumor may coexist in the animal; pre-B tumors may
predominate in vivo, but are gradually replaced by the T-cell component in
vitro.
The Mediator in Radiation Lymphomagenesis Remains Undefined.
￿
Earlier studies
(9, 24, 25) failed to reveal consistent evidence of RadLV etiology in radiation-
induced lymphomas of C57BL/Ka mice. Recently, Defresne et al. found no
RadLV-related antigens in T cell lymphomas produced by transfer of marrow
or thymic cells from irradiated mice (26). In the present study, RadLV has been
detected infrequently in either T or B cell lymphomas, which nevertheless were
clearly induced by a transmissible, lymphomagenic agent present in the marrow
ofirradiated mice. The concept ofRadLV-0 was introduced (10) to account for
the scarcity of RadLV expression in radiation lymphomas and for its frequent
de novo appearance on serial passage of tumor cells in vivo or in vitro. It
postulates that radiation induces a replication-defective, transformation-compe-
tent subviral entity, RadLV-0, which initiates and maintains the transformed
state in the absence of virus production, and is converted at a later stage to
infectious RadLV. In the present experiments, RadLV-0 could conceivably be
transmitted by cell-cell contact from marrow to thymic target cells. Because
RadLV has been detected in tumors induced by lethally irradiated, RadLV-
lymphoma cells, this possibility cannot be discounted. Theappearance ofRadLV
may however bea secondary phenomenon, resultingfrom increased opportunity
for recombination among the nonpathogenic retroviruses endogenous to
C57BL/Ka mice. We have previously shown that an otherwise nonthymotropic
ecotropic retrovirus, BL/Ka(B), replicates actively in lymphoma cells (29), and
furthermore, that lymphoma cells express elevated levels of xenotropic virus-
related mRNA (28). Arguing against the likelihood of RadLV-0 etiology is the
fact that the env recombination indicative of a leukemogenic retrovirus could
not be demonstrated at the DNA or RNA level in radiation-induced lymphomas
(28, 29). If the transmissible mediator of radiation lymphomagenesis is neither
RadLV nor RadLV-0, it must be antigenically distinct as well from the common
murine retroviruses, all of which are detected by the polyvalent rat regressor
serum used in these studies. Moreover, since reverse transcriptase activity has
consistently paralleled serological results, the agent may not be a retrovirus at
all. Current attempts to reveal the hypothetical virus include transmission studies
with subcellular tumor cell fractions, as well as cloning by screening cDNA
libraries with a probe constructed by subtracting mRNA from tumors induced
by cloned RadLV from primary radiation lymphoma cDNA. An alternative
explanation ofthe results could be the production ofa factor controlling growth
regulation. Such a factor, induced in bone marrow cells but acting on thymic
cells, might be akin to one described recently (30) in cultures of irradiated
stromal bone marrow cells in vitro. To account for the present observations,
however, the proposed growth factor would have to persist or induce its own
production in the cells it transforms, and be capable of transmission. Such
features blur the distinction between a growth factor-inducing element and an
infectious, autonomously replicating virus.The transmission of a lymphomagenic agent(s) from the bone marrow of
irradiated mice to thymic target cells has been demonstrated by: (a) the induction
of T cell lymphomas in nonirradiated thymic grafts implanted in irradiated, Thy-
1-congenic mice, (b) the induction of T cell lymphomas of host origin in mice
infused with bone marrow from irradiated, Thy-I-congenic donors. The latter
procedure also yields an appreciable number of pre-B cell lymphomas of uncer-
tain origin. The results confirm Kaplan's theory that radiation induces thymic
lymphomas in mice by an indirect mechanism. However, the previously described
radiation leukemia virus is clearly not involved in the majority of transferred
lymphomas. We propose that the mediating agent in radiation lymphomagenesis
is a novel, transmissible agent induced in the bone marrow, but exerting its
transforming activity on cells in the thymus. The nature and mode of action of
the agent are under investigation.
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